Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Yang, Zhe; Sun, Na; Cheng, Rui; Zhao, Chenyang; Liu, Jie; Tian, Zhongmin

doi:10.1039/c7tb01510k

Cited by 80 publications

(63 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As found with other tridimensional in vitro models and other PSs [14,32], TPCS 2a localized mainly in the more external cells layers of the mammospheres, and penetrated deeper at increasing incubation time. Weak penetration into the core of MCF-7 mammospheres was observed also with coumarin-loaded HA hybrid NPs [33].…”

Section: Discussionmentioning

confidence: 86%

CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro

Gaio

Conte

Esposito

et al. 2020

Cancers

View full text Add to dashboard Cite

The presence of rare but highly tumorigenic cancer stem cells (CSCs) within the tumors is recognized as one of the major reasons of failure of conventional chemotherapies, mainly attributed to the development of drug resistance and increasing metastatic potential. Here, we propose a therapeutic strategy based on the simultaneous delivery of docetaxel (DTX) and the photosensitizer meso-tetraphenyl chlorine disulfonate (TPCS2a) using hyaluronic acid (HA) coated polymeric nanoparticles (HA-NPs) for the targeting and killing of CD44 over-expressing breast cancer (BC) cells, both differentiated and CSCs (CD44high/CD24low population), thus combining chemotherapy and photodynamic therapy (PDT). Using the CD44high MDA-MB-231 and the CD44low MCF-7 cells, we demonstrated the occurrence of CD44-mediated uptake of HA-NPs both in monolayers and mammosphere cultures enriched in CSCs. Cell treatments showed that combination therapy using co-loaded NPs (HA@DTX/TPCS2a-NPs) had superior efficacy over monotherapies (HA@DTX-NPs or HA@TPCS2a-NPs) in reducing the self-renewal capacity, measured as mammosphere formation efficiency, and in eradicating the CSC population evaluated with aldehyde dehydrogenase activity assay and CD44/CD24 immunostaining. In summary, these in vitro studies demonstrated for the first time the potential of the combination of DTX-chemotherapy and TPCS2a-PDT for killing CSCs using properly designed NPs.

show abstract

Section: Discussionmentioning

confidence: 86%

CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro

Gaio

Conte

Esposito

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…44,45 Curcumin also has many functions such as antibacterial, anti-inflammatory, analgesic and wound healing properties, and its immunomodulatory potential in many inflammatory disease models has been demonstrated. 46,47 Moreover, studies have shown that curcumin protects against myocardial fibrosis through various mechanisms. For example, curcumin inhibits myocardial fibrosis by inhibiting the activation of MMP-9, TIMP-1 and fibroblasts.…”

Section: Discussionmentioning

confidence: 99%

Curcumin attenuates endothelial cell fibrosis through inhibiting endothelial–interstitial transformation

Chen

Shi

et al. 2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Curcumin (Cur) has various pharmacological activities, including anti-inflammatory, antiapoptotic and anticancer effects. However, there is no report on the effect of Cur on endothelial cell fibrosis. This study was designed to investigate the effect and mechanism of Cur on endothelial cell fibrosis. An endothelial cell fibrosis model was established by using transforming growth factor (TGF) induction. Proliferation assays, qRT-PCR, western blotting and immunostaining were performed to investigate the effects and mechanism of Cur on endothelial cell fibrosis. We found that in human umbilical vein endothelial cells (HUVECs), TGF-β1 treatment significantly decreased the expression of nuclear factor erythroid-2-related factor 2 (NRF-2), dimethylarginine dimethylaminohydrolase-1 (DDAH1), and VE-cadherin, the secretion of cellular nitric oxide (NO) and the activity of nitrous oxide synthase (NOS), while asymmetric dimethylarginine (ADMA) and the release of inflammatory factors were elevated.Immunofluorescence showed decreased CD31 and increased α-smooth muscle actin (α-SMA). Overexpression of NRF-2 significantly attenuated the effects of TGF-β1, while downregulation of DDAH1 potently counteracted the effect of NRF-2. In addition, ADMA treatment resulted in similar results to those of TGF-β1, and Cur significantly attenuated the effect of TGF-β1, accompanied by increased VE-cadherin, DDAH1 and NRF-2 and decreased matrix metalloproteinase-9 (MMP-9) and extracellular regulated protein kinases 1/2 (ERK1/2) phosphorylation. The NRF-2 inhibitor ML385 had the opposite effect as that of Cur. These results demonstrated that Cur inhibits TGF-β1-induced endothelial-to-mesenchymal transition (EndMT) by stimulating DDAH1 expression via the NRF-2 pathway, thus attenuating endothelial cell fibrosis. K E Y W O R D Scurcumin, endothelial-to-mesenchymal transition (EndMT),

show abstract

“…They showed that the HA‐PLGA NPs delivered drugs to breast cancer in vitro and in vivo and reduced number and migration of breast cancer stem cells (bCSCs) by targeting their surface marker CD44. More importantly, HA‐hybrid co‐delivered NPs showed significant tumor growth inhibition by synergistically inhibiting the proliferation of non‐bCSCs and bCSCs in MCF7 xenografted tumor models . Wang et al.…”

Section: Nanocarriersmentioning

confidence: 99%

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Peng

Bariwal

Kumar

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Nanocarriers have the capability to deliver a variety of drugs to disease sites. Different biological barriers prevent the successful delivery of nanoformulations to target sites, thereby limiting effective therapeutic response. Although numerous efforts have been made to design novel nanocarriers by incorporating various functionalities to get better therapies, most strategies have failed to translate drug delivery systems to the clinic. Impediments such as the incapability to hold drugs stably in nanocarriers during circulation, non‐specific distribution, and inadequate delivery of therapeutic agents to target sites due to complex tumor microenvironment remain a challenge. Herein, different organic polymer and lipid‐based nanocarriers and their encouraging therapeutic effectiveness to treat cancer are discussed. Recent development in multifunctional and stimuli sensitive nanocarriers is also highlighted. Finally, the challenges and innovative strategies to overcome various obstacles and limitations for their successful translation into the clinic are discussed.

show abstract

Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Abstract: HA-modified hybrid nanoparticles for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells.

Cited by 80 publications

References 42 publications

CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro

CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro

Curcumin attenuates endothelial cell fibrosis through inhibiting endothelial–interstitial transformation

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Contact Info

Product

Resources

About